导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.43% | 1499/4783 |
| 近一周 | -7.99% | 3978/5283 |
| 近一月 | -6.43% | 3668/5237 |
| 近一季 | -2.26% | 2632/5027 |
| 近半年 | -2.91% | 2662/4807 |
| 近一年 | 26.40% | 1444/4070 |
| 近两年 | 52.53% | 1193/2862 |
| 近三年 | 26.50% | 1094/2177 |
| 成立以来 | 74.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.97% 1116/4961 |
18.01% 1429/5312 |
- - |
- - |
| 2025 | 26.18% 1651/4813 |
1.69% 1573/3635 |
2.60% 1471/4076 |
20.96% 1890/4524 |
-0.01% 2296/4813 |
| 2024 | 5.75% 1815/3463 |
-2.02% 1306/2808 |
-4.31% 1496/3014 |
13.87% 2088/3129 |
-0.95% 1551/3463 |
| 2023 | -7.22% 902/2656 |
7.55% 554/2280 |
-3.75% 888/2385 |
-4.57% 1167/2515 |
-6.07% 1621/2655 |
| 2022 | -17.19% 562/2207 |
-12.10% 572/1919 |
2.84% 1249/2016 |
-10.35% 386/2113 |
2.18% 1015/2208 |
| 2021 | 15.94% 290/1822 |
0.45% 293/1255 |
8.15% 644/1330 |
5.65% 262/1466 |
1.01% 1023/1822 |
| 2020 | 31.07% 507/1250 |
-1.53% 224/1028 |
15.09% 517/1067 |
10.02% 596/1164 |
5.12% 804/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中泰中证500指数增强A VS. 长安沪深300非周期A(740101) |